Evidence map›Paper›PMID 40970827›Full record

ArticleChemistryOpen2025

Polylactic- Glycolic Acid Microparticles-Encapsulated Prostaglandin E1 as A Novel Strategy In Triple Negative Breast Cancer.

Concetta Di Natale, Elena Lagreca, Raffaele Crispino, Roberta D'Auria, Alessandro Attanasio, Rezvan Jamaledin, Raffaele Vecchione, Paolo Antonio Netti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemistryOpen, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Concetta Di NataleDipartimento di Ingegneria Chimica, dei Materiali e della Produzione Industriale, University of Naples Federico II, P. le Tecchio 80, Napoli, I-80125, Italy.ORCID 0000-0002-2874-6539
Elena LagrecaDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.ORCID 0000-0003-0500-8610
Raffaele CrispinoDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Roberta D'AuriaDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Alessandro AttanasioDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Rezvan JamaledinDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.ORCID 0000-0003-2389-3393
Raffaele VecchioneDepartment of Life Science, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Paolo Antonio NettiDipartimento di Ingegneria Chimica, dei Materiali e della Produzione Industriale, University of Naples Federico II, P. le Tecchio 80, Napoli, I-80125, Italy.

Funding

Fondazione Umberto Veronesi Post-Doctoral Fellowship
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is characterized by unique clinical and pathological traits, from which its aggressive nature and the absence of specific treatments are the most worrying. Prostaglandin E

Indexed as

AlprostadilAntineoplastic AgentsDrug CarriersPolylactic Acid-Polyglycolic Acid CopolymerTriple Negative Breast NeoplasmsCaco-2 CellsCell Line, TumorCell SurvivalDrug LiberationFemaleGlycolatesHumansParticle SizeAlprostadilAntineoplastic AgentsDrug CarriersGlycolatesglycolic acidPolylactic Acid-Polyglycolic Acid Copolymercell cytotoxicitiesdrug deliveriespolylactic‐ glycolic acid microparticlesprostaglandins E1triple breast cancers

Identifiers

PMID40970827
PMCPMC12680548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.